138,300 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 138,300 shares of the company’s stock, valued at approximately $11,036,000. Healthcare of Ontario Pension Plan Trust Fund owned about 0.29% of Axsome Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Principal Financial Group Inc. lifted its holdings in Axsome Therapeutics by 1.3% in the fourth quarter. Principal Financial Group Inc. now owns 9,497 shares of the company’s stock worth $756,000 after buying an additional 120 shares during the period. CIBC Private Wealth Group LLC raised its position in shares of Axsome Therapeutics by 0.8% in the 4th quarter. CIBC Private Wealth Group LLC now owns 17,999 shares of the company’s stock worth $1,433,000 after acquiring an additional 135 shares in the last quarter. Washington Trust Advisors Inc. purchased a new position in shares of Axsome Therapeutics in the 4th quarter valued at approximately $26,000. Oak Ridge Investments LLC boosted its position in shares of Axsome Therapeutics by 2.7% during the first quarter. Oak Ridge Investments LLC now owns 15,930 shares of the company’s stock valued at $1,271,000 after purchasing an additional 413 shares in the last quarter. Finally, Janney Montgomery Scott LLC grew its stake in Axsome Therapeutics by 9.5% in the first quarter. Janney Montgomery Scott LLC now owns 5,780 shares of the company’s stock worth $461,000 after purchasing an additional 500 shares during the period. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Insider Transactions at Axsome Therapeutics

In related news, COO Mark L. Jacobson sold 7,910 shares of the business’s stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $74.31, for a total transaction of $587,792.10. Following the completion of the sale, the chief operating officer now directly owns 5,783 shares in the company, valued at $429,734.73. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, COO Mark L. Jacobson sold 7,910 shares of Axsome Therapeutics stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $74.31, for a total transaction of $587,792.10. Following the transaction, the chief operating officer now owns 5,783 shares in the company, valued at approximately $429,734.73. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark Coleman sold 5,249 shares of the business’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $75.21, for a total transaction of $394,777.29. Following the sale, the director now directly owns 19,848 shares of the company’s stock, valued at approximately $1,492,768.08. The disclosure for this sale can be found here. Company insiders own 22.40% of the company’s stock.

Analyst Ratings Changes

AXSM has been the topic of a number of research reports. Cantor Fitzgerald restated an “overweight” rating and set a $107.00 target price on shares of Axsome Therapeutics in a report on Wednesday, April 10th. Needham & Company LLC started coverage on Axsome Therapeutics in a research report on Monday. They issued a “buy” rating and a $130.00 price target on the stock. Bank of America reduced their price objective on Axsome Therapeutics from $97.00 to $95.00 and set a “neutral” rating for the company in a research report on Thursday, July 18th. Morgan Stanley raised Axsome Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $90.00 to $115.00 in a report on Monday, April 29th. Finally, Citigroup cut their target price on Axsome Therapeutics from $127.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, May 7th. One analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $123.85.

Axsome Therapeutics Stock Performance

AXSM traded up $0.15 during mid-day trading on Thursday, reaching $85.38. 245,614 shares of the company traded hands, compared to its average volume of 709,036. The stock has a market capitalization of $4.06 billion, a P/E ratio of -13.36 and a beta of 1.26. Axsome Therapeutics, Inc. has a 52-week low of $55.02 and a 52-week high of $98.40. The company has a quick ratio of 3.09, a current ratio of 3.20 and a debt-to-equity ratio of 1.25. The company’s fifty day moving average price is $78.16 and its 200-day moving average price is $79.50.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, May 6th. The company reported ($1.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.11. The company had revenue of $75.00 million for the quarter, compared to the consensus estimate of $69.91 million. Axsome Therapeutics had a negative return on equity of 87.17% and a negative net margin of 118.07%. On average, sell-side analysts expect that Axsome Therapeutics, Inc. will post -4.66 EPS for the current year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.